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Improving adherence to anti-tuberculosis (TB) treatment is a public health priority in 39 
high income, low incidence (HILI) regions. We conducted a scoping review to identify 40 
reported determinants of non-adherence in HILI settings. 41 
 42 
Methods 43 
Key terms related to tuberculosis, treatment, and adherence were used to search 44 
MEDLINE, EMBASE, Web of Science, PsycINFO, and CINAHL in June 2019. 45 
Quantitative studies examining determinants (demographic, clinical, health systems, 46 




From 10,801 results, we identified 24 relevant studies from 10 countries. Definitions 51 
and methods of assessing adherence were highly variable, as were documented 52 
levels of non-adherence (0.9%–89%). Demographic factors were assessed in all 53 
studies and clinical factors frequently assessed (23/24). Determinants commonly 54 
associated with non-adherence were homelessness, imprisonment, and alcohol or 55 
drug misuse. Health system (8/24) and psychosocial factors (6/24) were less 56 
commonly evaluated. 57 
 58 
Conclusion 59 
Our review identified some key factors associated with non-adherence to anti-TB 60 
treatment in HILI settings. Modifiable determinants such as psychosocial factors are 61 
under-evidenced and should be further explored as these may be better targeted by 62 
adherence support. There is an urgent need to standardise definitions and 63 
measurement of adherence to more accurately identify the strongest determinants.   64 




Despite the availability of effective, low-cost medication, tuberculosis (TB) remains a 67 
global health concern 1. One reason for this is non-adherence to anti-TB treatment, 68 
which increases morbidity and mortality 2,3, transmission, the development of drug 69 
resistance, and health disparity 4–6. 70 
  71 
We have yet to identify the best adherence support for anti-TB treatment. Directly-72 
observed therapy (DOT) has been recommended by the World Health Organization 73 
(WHO) since the 1990s 7, but research does not consistently find DOT superior to 74 
self-administered therapy (SAT) in reducing adverse treatment outcomes such as 75 
loss to follow-up 8,9. Furthermore, improved outcomes from DOT dissipate when 76 
patients receiving SAT have increased contact with healthcare services 8, suggesting 77 
the benefit of DOT may result from the “encounter” rather than the “observation”. 78 
This is important as DOT is resource-intensive, and can be perceived negatively by 79 
patients 10–12.  80 
 81 
Interventions to support adherence are more likely to be effective if they address the 82 
specific causes of non-adherence relevant to the individual patient 13,14. Identifying 83 
specific, and potentially modifiable, determinants of adherence to anti-TB treatment 84 
is therefore critical in developing more targeted and effective support 15. 85 
 86 
Improving anti-TB treatment adherence is a priority for high income, low TB 87 
incidence (HILI) countries progressing toward TB elimination 16. To date, 88 
determinants have mostly been examined in high incidence regions 17–19. 89 
Determinants in high and low incidence regions may differ, based on differences in 90 
populations with TB and resources for care 20–22. Therefore, as formative research 91 
for an intervention to promote adherence to anti-TB treatment in the UK 23, we 92 
undertook a scoping review to explore determinants of non-adherence to anti-TB 93 
treatment within HILI settings, and identify evidence gaps relevant to patients and 94 






We selected a scoping review methodology to provide a broad overview and 99 
highlight key evidence gaps 24, given expectations of study heterogeneity 25,26 and 100 
diverse definitions and measurements of TB treatment adherence 27. The Preferred 101 
Reporting Items for Systematic Reviews and Meta-Analyses Extension Checklist for 102 
Scoping Reviews (PRISMA-ScR) was used 25. 103 
 104 
Literature search 105 
Five databases (MEDLINE, EMBASE, Web of Science, PsycINFO, and CINAHL) 106 
were searched in June 2019. Researchers developed and refined search terms 107 
related to TB, treatment, and adherence, with support from an experienced librarian 108 
(Supplementary Material 1).  109 
 110 
Search terms were mapped to the Population-Concept-Context framework 111 
recommended for scoping reviews 28 (Table 1). Identified studies were imported into 112 
Endnote 29 and duplicates were removed. Two authors independently screened titles 113 
and abstracts using the website Rayyan, designed for article screening in reviews 30. 114 
Any discrepancies were resolved through discussion. Reference lists of included 115 
studies were hand-searched to identify additional relevant studies. 116 
  117 
Eligibility criteria are listed in Table 1. Included studies were peer-reviewed, English 118 
language studies, whose aim was to report primary, observational, quantitative data 119 
on determinants of non-adherence to anti-TB treatment, in countries classified as 120 
high income 31 with low TB incidence rates (<40 per 100,000 people), when the 121 
study was conducted. We included outcomes of both discontinuation (early cessation 122 
of treatment, including loss to follow-up) and suboptimal implementation (missing 123 
doses during treatment) 32–34. We excluded qualitative research, as our research 124 
group has reviewed this separately 35.  125 
 126 
Data extraction and synthesis 127 
Two authors independently extracted data (cross-checking 50% of studies). 128 
Determinants were included if studied as primary exposures of interest or potentially 129 
confounding factors. Determinants were labelled as demographic, clinical, health 130 
systems-related, or psychosocial.   131 
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Categorises were used to reflect the strength of evidence for each determinant. A 132 
proxy measure was created for this, based on the size and direction of the effect size 133 
(ES) estimate and statistical certainty. Evidence was classified from strongest to 134 
weakest using the following categories: 135 
 Category 1: Strongest: ES (ratio) ≥1.5, p-value ≤0.05; 136 
 Category 2: ES (ratio) ≥1.5, p-value >0.05, small sample size (n <154) i.e. 137 
study likely to be under-powered; 138 
 Category 3: ES (ratio) >1.0 to <1.5, p-value ≤0.05; 139 
 Category 4: Weakest: ES (ratio) >1.0, p-value >0.05. 140 
The equivalent categories were used to classify determinants observed to have a 141 
protective effect. In order to provide a standardised classification for category 2, a 142 
sample size calculation was required. It was calculated that a minimum of 154 143 
participants would indicate an adequately powered sample size, using 90% power 144 
and 5% significance level, statistically conservatively assuming that 50% of 145 
individuals had the outcome among the unexposed, and assuming a one-to-one ratio 146 
of exposed to unexposed or cases to controls. Although this threshold did not 147 
perfectly reflect the analyses in all studies, it provided a framework for weighting the 148 
evidence of each determinant. It did not indicate judgement on the quality of included 149 
studies. Where possible, determinants were classified based on ES in multivariable, 150 
not univariable, analyses. 151 
 152 
Ethics 153 
Ethics approval was not required as this was a scoping review. 154 
 155 
RESULTS 156 
Description of included studies 157 
The initial search found 10,801 studies. After removing duplicates, 9,932 remained 158 
for title and abstract screening, and 25 met the inclusion criteria (Figure 1, 159 
Supplementary Material 2). Data on determinants were extracted for 24 studies, as 160 
one 36 reported no ES.  161 
 162 
Included studies were published 1986-2019, from 10 different countries, including 163 
the UK and Ireland (n=7) 37–43, USA (n=6) 36,44–48, and Spain (n=5) 49–53. The most 164 
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common study design was retrospective cohort (n=12) 37,40,46,48,49,53–59. Sample sizes 165 
ranged from 62 to 73,591 (median= 1009; interquartile range (IQR)= 184-2576). The 166 
mean/median participant age ranged from 28.0 to 52.1 years. The median 167 
percentage of males was 64.4% (IQR= 56.0-71.0%).  168 
 169 
Most studies (n=20) included all patients starting treatment in a given setting 36–170 
45,47,48,50–52,54–58. Three studies sampled specific high-risk groups, of people 171 
experiencing homelessness or unstable living arrangements 60, individuals with 172 
multidrug-resistant TB (MDR-TB) 59, or HIV/TB co-infection 53. Two studies compared 173 
outcomes between groups within a cohort, such as immigrants versus individuals 174 
born within a country 46,49. 175 
 176 
 177 
Non-adherence: definitions and assessment 178 
Supplementary Material 2 demonstrates the considerable variability in definitions of 179 
adherence. Most study outcomes (n=15) related to treatment discontinuation 180 
(stopping treatment early) 38,40,44–47,49,50,53–56,58–60. Fewer study outcomes (n=7) 181 
appeared to record suboptimal implementation (missed doses during treatment) 182 
36,37,39,41,43,48,57. One study included both a discontinuation and suboptimal 183 
implementation outcome 42. Two studies used a single outcome encapsulating both 184 
discontinuation and suboptimal implementation 51,52.  185 
 186 
Discontinuation outcomes were often measured using state or national 187 
registries/surveillance databases 40,44–47,53–55,58,59, hospital/lab records 44,45,47,49,59, or 188 
medical notes 38,60.  189 
 190 
Sub-optimal implementation was assessed using various methods, including 191 
adherence scale scores 36, medical records 57, physician impression from 192 
interviews/assessments 39,41, patient self-report 39, health visitor reports (including pill 193 
counts) 41, urine samples (to detect rifampicin) 39,43, attendance at appointments 194 
41,48,57, and prescription requests 48,57. 195 
 196 
Overall, retrospective studies most often used surveillance/registry data to determine 197 
adherence 37,40,45–47,53–55,58,59, whereas prospective studies used more varied 198 
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methods (Supplementary Material 2). Reported non-adherence ranged from 0.9% to 199 
89% across studies (median= 7.0%; IQR= 5.2-16.3%). Two studies did not report 200 
levels of non-adherence 36,60. 201 
 202 
Determinants of non-adherence 203 
Demographic determinants 204 
Demographic determinants were assessed by all 24 studies (Supplementary Material 205 
2). Specifically, the most studied determinant groups were place of residence and 206 
age (Supplementary Material 3). The variable with the greatest strength of evidence 207 
for a large effect on non-adherence (Categories 1 or 2- large effect sizes with p-208 
value≤0.05 or a small sample size, see Methods; Supplementary Material 2) was 209 
place of residence (Figure 2). Within that variable, homelessness 37,42,44,46–48,50,53,57,60 210 
and living in an institution or prison (e.g. a “confined institution”, a residence hall, or 211 
mental hospital) 37,42,46,47,51,52,55,58 had the strongest evidence, weighted overall, 212 
towards non-adherence (Supplementary Material 2).  213 
 214 
Age, sex, ethnicity, and nationality also showed mixed evidence of effects, as within 215 
each variable just as many or more studies found a weak effect with non-adherence 216 
as a large effect (Figure 2). Ethnicity and nationality determinants appeared very 217 
context-specific, demonstrated by the variation in baseline comparators within these 218 
categories. Overall, few demographic determinants were classified in categories 2 219 
(i.e. large ES, p-value>0.05, but small sample size) or 3 (small ES, p-value≤0.05) in 220 
terms of strength of evidence. The grouping variables most commonly found to have 221 
a weak effect on adherence (category 4, small ES, p-value>0.05) were age, 222 
nationality/origin, and ethnicity. No variable had a consistently large effect with non-223 
adherence.  224 
 225 
Clinical determinants 226 
Clinical determinants were the second most studied category (23/24 studies 227 
Supplementary Material 2). The substance use/misuse grouping variable was the 228 
most frequently assessed and had the most evidence weighted towards a large 229 
effect (Supplementary Material 3 and Figure 2). Specifically, illicit drug 230 
misuse/addiction had the strongest evidence for this 48,50–52,55 (Supplementary 231 
Material 2). The evidence for clinical determinants was also mixed, in terms of both 232 
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strength of evidence and direction. For example, in the HIV grouping variable, HIV 233 
positive status was a risk factor for non-adherence 50,51,55, yet a diagnosis of AIDS 234 
was protective against non-adherence 44,46 (Supplementary Material 4). Again, few 235 
determinants fell into categories 2 and 3 in terms of strength of evidence, and the 236 
grouping variables which most commonly showed a weak effect with adherence 237 
were smear and sputum result, substance use/misuse, and HIV infection. 238 
 239 
Health systems determinants 240 
Health systems determinants were less frequently investigated (8/24 studies). Within 241 
this category, route to care was the most studied grouping variable (Supplementary 242 
Material 3). Healthcare professionals’ perception of patient understanding (e.g. lack 243 
of awareness of TB severity, understanding of treatment instructions, language 244 
barriers) had a consistently large effect with non-adherence, though this determinant 245 
was minimally studied. The grouping variables most often found to have a weak 246 
effect with adherence were route to care, and those classified as “other”. 247 
 248 
Psychosocial determinants 249 
Psychosocial determinants were the least studied (6/46 studies), where only mental 250 
health and having close relationships were assessed (Supplementary Material 3, 251 
Figure 2). Of these, having a mental health problem was both a risk for 42 and 252 
protective against non-adherence 47 (Supplementary Material 2). Strength of 253 
evidence for mental health problems was also mixed, with as many studies finding 254 
strong and weak effects on adherence.  255 
 256 
DISCUSSION 257 
In our scoping review investigating the determinants of non-adherence to anti-TB 258 
treatment within HILI settings, homelessness, imprisonment, and alcohol or drug 259 
misuse were commonly associated factors. Health systems and psychosocial 260 
determinants were under-explored. Considerable heterogeneity in measurements 261 
and definitions of non-adherence was present across studies, hindering the 262 
conclusions that can be drawn.  263 
 264 
When synthesising the literature on determinants, we found that demographic and 265 
clinical factors were most studied. This may reflect the relative ease of capturing this 266 
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data through TB surveillance in HILI settings, such as the UK 61. However, the 267 
context required to understand mixed findings for these determinants was largely 268 
missing from studies, which may result from utilising these data sources. Without 269 
context, these findings are unhelpful for explaining non-adherence. For example, a 270 
recent systematic review found that despite assumptions, non-adherence was as 271 
likely to occur in both migrants and non-migrants 62. Such findings highlight the 272 
importance of contextualising demographic and clinical determinants, if researchers 273 
are to utilise this data in intervention design. 274 
 275 
In addition, demographic and clinical determinants are largely non-modifiable (e.g. 276 
history of imprisonment) or difficult to change (such as homelessness, illicit drug 277 
use/addiction) within a feasible, scalable healthcare intervention 63. Improving 278 
adherence to anti-TB treatment requires identifying potentially modifiable 279 
determinants that can be targeted within a pragmatic, person-centred healthcare 280 
intervention.  281 
 282 
Determinants more amenable to change, such as health systems issues, have rarely 283 
been quantitatively assessed in HILI settings. Health systems barriers in high 284 
incidence regions, such as distance to treatment facilities and transport costs 17–19, 285 
may be less apparent in HILI countries with better-resourced health services. 286 
Nonetheless, they may affect subgroups of patients, given that TB disproportionately 287 
affects people with lower socioeconomic status in high income settings 20. In 288 
addition, health systems determinants may interact with other factors (such as fear of 289 
stigma making an individual seek care at a more distant hospital), reinforcing the 290 
need to better understand their influence in HILI settings.  291 
 292 
Psychosocial determinants are also under-researched in quantitative literature on TB 293 
adherence. This oversight is significant given the known relationship between TB, 294 
stigma, and adherence, even in low incidence settings 64. Understanding the social 295 
context of TB treatment is significant for reaching TB control goals, given the well-296 
established links between social determinants of health and inequality 65, even within 297 




Theory in behavioural medicine suggests adherence is best viewed as a modifiable 300 
behaviour and not a trait 67, as adherence patterns can change within an individual 301 
over time 32,68, and also differ between people with shared demographic 302 
characteristics. Theory and evidence suggest that amendable, cognitive and 303 
affective factors, such as beliefs about illness and treatment, influence subsequent 304 
coping strategies, including treatment adherence 69–71. Understanding psychosocial 305 
determinants may enable us, therefore, to provide better adherence support.  306 
 307 
Evidence from this review has important clinical implications for intervention 308 
development in TB. Interventions should: 1) accurately assess known risk factors for 309 
non-adherence to anti-TB treatment in HILI settings; and 2) mitigate the influence of 310 
these on perceptual and practical barriers to adherence 70. For example, 311 
interventions should be tailored to both target a patient’s beliefs about TB and 312 
treatment, and provide practical support to overcome personal barriers to treatment. 313 
 314 
Our scoping review followed PRISMA-ScR guidelines to systematically search the 315 
available literature. We may have been limited by including only English language 316 
studies. We may have missed secondary data reported (e.g. in intervention studies) 317 
by only including studies whose primary aim was to examine determinants of non-318 
adherence. In addition, as this was a scoping review, the quality of included studies 319 
was not assessed.   320 
 321 
Our understanding of non-adherence to anti-TB treatment within HILI settings is 322 
severely limited by the heterogeneity of included studies. Clearer and consistent 323 
definitions of which type of non-adherence is being assessed in studies 33, and data 324 
presented beyond simple binary summary measures, are urgently needed 72.  325 
 326 
By including all data on reported determinants, whether measured as primary 327 
exposures of interest or potential confounding factors, some estimates may be 328 
subject to bias. Of note, few (n=2) studies assessed all four categories of 329 
determinants and therefore adjusted for confounders appropriately. This 330 
considerably impairs our ability to understand the interaction between determinants 331 
and their relationship to non-adherence, and may explain the inconsistency of the 332 




In conclusion, this scoping review identifes determinants with the best supportive 335 
evidence, and highlights a gap in our understanding of adherence to anti-TB 336 
treatment in HILI settings. Understanding how demographic and clinical 337 
determinants are associated with adherence to anti-TB treatment is necessary to 338 
inform intervention development. Qualitative work could extend current 339 
understanding by examining how health systems and psychosocial factors influence 340 
anti-TB treatment in HILI settings 23. Stakeholders in TB policy and service 341 
implementation should also consider how factors influencing patient adherence are 342 
currently evaluated and understood. Existing care practices, such as risk 343 
assessments, should ensure the range of complex factors involved in adherence are 344 
comprehensively addressed.  345 
 346 
We also identified a need for greater consistency in definitions and measurement of 347 
adherence within the TB literature. Without this, it will remain difficult to effectively 348 
synthesise data, and understand reported patterns of adherence behaviour. 349 
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Inclusion criteria Exclusion criteria 




Studies reporting data 
on non-adherence to 
treatment for 
pulmonary tuberculosis. 
 Studies with a non-
human sample. 
 Studies with patients 
taking prophylactic TB 
treatment or treatment 
for latent TB. 
 Studies where the 
majority of patients 
(>50%) had extra-
pulmonary disease. 
 Studies with a co-
morbid sample 
(excluding HIV).  
 















standard treatment, or 
more than 50% of the 
sample was receiving 
DOT/VOT). 
 Qualitative studies. 
 Studies that were not 
primary research 
articles (e.g. reviews, 
commentaries, or 
letters).  
 Studies that did not 
measure determinants 
of non-adherence.  
 Studies where 
treatment completion 
was the outcome (as 
this is conflated with 
successful treatment 
outcome and is not a 
measure of patient 
adherence). 




as high income and 
low TB incidence at 
time of study.   
 Studies in settings 
defined as low and 
middle income, or 
with high TB 
incidence.  
Note. DOT= directly-observed therapy; HILI= high income, low (TB) incidence; TB= 609 
tuberculosis; VOT= video-observed therapy. 610 
  611 
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List of Figures 612 
 613 
Figure 1. PRISMA diagram of screening process and included studies. 614 
 615 
Figure 2. Determinants of non-adherence to TB treatment. Note. Bars may include 616 
multiple determinant levels assessed within the same study. Darkest grey indicates 617 
the strongest effect (i.e. category 1: a large risk or protective effect at p<.05), 618 
medium grey indicates a large risk or protective effect at p>.05 with a small sample 619 
size (category 2), light grey indicates a small risk or protective effect at p<.05 620 
(category 3), and lightest grey indicates the weakest effect found at p>.05 (category 621 
4). HCP = healthcare professional, SES= socioeconomic status, TB= tuberculosis 622 
 623 
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Records identified through 




































Additional records identified 
through hand searching  
(n= 2) 
Records after duplicates removed 
(n= 6377) 
Records screened  
(n= 6377) 
Records excluded  
(n= 6087) 
Full-text articles excluded, 
with reasons  
(n= 265) 
 Setting (high 
incidence and/or low 
or middle income 
country) (n= 244) 
 Adherence outcome 
not suitable (n= 15) 
 Determinants not 
measured (n= 4) 
 Directly observed 
therapy (n= 2) 
Studies included in 
scoping review  
(n= 25) 
Full-text articles 
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 651 
652 
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Supplementary material 1  
 
Scoping review search example strategy from MEDLINE 
 
1. Tuberculosis/  
2. (TB or tuberculo*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism supplementary 
concept word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
3. 1 or 2 
4. Drug Therapy/ 
5. (medication* or medicine* or treatment* or therap*).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, floating sub-heading word, keyword 
heading word, organism supplementary concept word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier, synonyms] 
6. 4 or 5 
7. 3 and 6 
8. Antitubercular Agents/ 
9. 7 or 8 
10. Medication Adherence/ or "Treatment Adherence and Compliance"/ 
11. (adheren* or complian* or non-adheren* or non-complian* or nonadheren* or concordan* or 
non-concordan*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism supplementary 
concept word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
12. (LTFU or “los* to follow-up” or “los* to follow up” or LFU or default).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, floating sub-heading word, 
keyword heading word, organism supplementary concept word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms] 
13. Lost to Follow-Up/ 
14. 10 or 11 or 12 or 13 
15. 9 and 14 


























Not given 90 Ireland Patients being treated for 
pulmonary TB and discharged 






report or physician’s 
impression from 
interview 
Non-compliance: based on 
interview evidence and ≥1 
negative urine sample(s). 
23.3 Corcoran 39 
Not given 113 UK Patients being treated at Leeds 






Urine sample Non-compliance: negative 
urine sample. 
7.0 Wardman et 
al. 43 
1988-1989 224 USA Patients being treated in Harlem 





State TB registry 
data and hospital 
records 
Noncompliance: no follow-up 
treatment or LTFU. 
89.0 Brudney & 
Dobkin 44 
1995–1996 62 USA Patients being treated and 





Scale (TBGAS)  









1999–2000 1515 Spain Patients being treated by a 
member of the Tuberculosis 
and Respiratory Infections 
Group of the Sociedad 
Española de Neumología y 



















Default: no treatment 
received for >1 month or 
missed appointments. 

















1998–2003 119 Japan Homeless patients or those in 
fragile living situations who 
received treatment in a Tokyo 
hospital (excluded patients with 








Medical notes  Treatment interruption during 
outpatient care: no treatment 






Kizuki et al. 60 
2000–2003 575 UK Patients being treated in the 






(extracted by TB 
staff) 
LTFU 7.8 Anyama et al. 
38 
2003 1941 UK Patients in Greater London who 


















reported, inconsistent pill 
counts, negative urine test, 
or patients switched to DOT 
or hospitalised for poor 
adherence.    
 
LTFU: being out of contact 
with services for at ≥2 
months without medication 









Story et al. 42 
2006–2007 1490 Spain Patients being treated by a 
member of the Tuberculosis 
and Respiratory Infections 
Group of the Sociedad 
Española de Neumología y 
Cirugía Torácica (SEPAR) 
(excluded patients with known 
drug resistance or those not 












Poor adherence: including 
default (treatment 
interruption for >2 months, 
non-completion by 9-months 
on standard regimen, or 
<80% prescribed doses 
taken) and LFTU. 

















2006–2009 1490 Spain Patients being treated with 
culture-positive or smear-
positive disease, 
extrapulmonary TB with 
caseating granuloma, 
identification by histology, or 
clinical, radiological, 
epidemiological or laboratory 
suspicion of TB (excluded 
patients with known drug-
resistance or those with a 







Not specified LFTU: treatment interruption 
(any reason) for ≥2 months, 
non-completion of treatment 
within 9 months for standard 
therapy, or taking <80% of 
prescribed dose. 
6.48 Rodrigo et al. 
52 
Retrospective designs 
1988–1992 103 Switzerland Patients with bacteriologically 
confirmed pulmonary TB being 









medical records)  
Not adherent: not specified 
(adherence considered 
satisfactory if patient 
attended scheduled visits 
and requested prescriptions). 
18.4 Zellweger & 
Coulon 57 
1993 2576 USA Compared patients being 
treated in California who did 
and did not move during 









Default: patients who refused 
treatment or were LTFU. 
5.5 Cummings et 
al. 46 
1991–1994 184 USA Patients with a first time, 
positive-culture being treated in 











attending clinic appointments 
for ≥2 months, or ≥3 months 
during 1 year. 
48.0 Pablos-
Mendez et al. 
48 
1993–1994 3520 USA Patients with culture-confirmed, 
rifampin- susceptible TB, 
starting a rifampin-containing 
regimen of at least 60 days, 






State TB registry 





without experiencing serious 
adverse effects related to 
use. 

















1987–1996 1354 Spain Patients with HIV/TB co-
infection, detected by the Active 
Epidemiological Surveillance 
System of the Barcelona 
Tuberculosis Prevention and 
Control Programme, being 








LTFU or failed medical 
controls and not found by 
public health surveillance 
nursing team. 
13.1 Galdós 
Tangüis et al. 
53 
1993–1997 7529 The 
Netherlands 







National TB registry 
data 
LTFU (excludes patients 
reportedly continuing 
treatment elsewhere) 
8 Borgdorff et al. 
58 
1998–2002 328 USA Patients who were culture-
positive being treated in New 
















interrupted for ≥60 days) with 
return to therapy 
 
Default without return to 
therapy (including LTFU or 
treatment refusal) 
4.2 Driver et al. 47 
2001–2007 41,120 UK Patients being treated in 
England, Wales and Northern 
Ireland reported to the 
Enhanced Tuberculosis 







LTFU (before treatment 
completion, including 
patients who moved 
overseas) 
5.9 Millet et al. 40 
2000–2011 503 Spain Compares immigrant and native 







Hospital records Treatment abandonment: 
treatment interrupted for ≥2 
months (without medical 
advice), or LTFU with no 
information available. 
1.8 Ballesteros et 
al. 49 

































2000–2013 27,894 Portugal Patients with pulmonary TB 
being treated in continental 
Portugal, as identified through 









interrupted for >8 weeks 
after completing ≥1 month of 
treatment) 
4.9 Nunes et al. 55 
1995–2014 68 Norway Patients with MDR-TB being 







TB registry data 
LTFU: WHO 2013 definition 
(no treatment initiation, or 
treatment interrupted for ≥2 
consecutive months). 
17.6 Jensenius et 
al. 59 
2006–2015 73,591 Japan Patients with pulmonary TB 








LTFU: definition from 
Japanese TB surveillance 
system (treatment 
interrupted for ≥2 
consecutive months, or 
treatment duration <6 
months). 
7.8 Kawatsu et al. 
54 
1997–2017 190 France Patients diagnosed at Dron 
Hospital in Tourcoing (excluding 







(appears to be 
medical and 
laboratory records) 
LTFU: no treatment initiation 
or treatment interrupted for 
≥2 consecutive months.  
15.0 Tetart et al. 56 
Mixed designs 











counts) and clinic 
attendance 
Poor compliance: ≥3 missed 
appointments or 
unfavourable assessments. 
3.0 Ormerod & 
Prescott 41 
Note. *determinants not extracted for this study. TB= Tuberculosis; LTFU= Loss to follow-up; MDR-TB= Multidrug-resistant 








Determinant grouping variable Studies assessing determinant grouping 
variable:  
Demographic Age n= 14  
37 38 40 41 42 46 47 49 50 51  
53 58 59 55 
Sex n= 14 
38 40 42 43 44 48 50 51 53 57 58 59 54 55  
Ethnicity n= 5 
40 42 45 46 48 
Nationality/origin n= 7 
37 38 43 48 58 59 54 
Residency/Immigration status n= 9 
40 49 50 51 52 56 57 58 55 
Place of residence (e.g. homelessness, history of 
living in an institution or prison) 
n= 16 
37 42 44 46 47 48 49 50 51 52 53 57 58 54 55 60 
Employment status n= 4 
51 56 54 60 






Determinant grouping variable Studies assessing determinant grouping 
variable:  
SES indices (e.g. primary education only, living in low 
SES neighbourhood) 
n= 5 
38 39 43 53 54  
Other (e.g. relationship status, receiving leave for 
appointments, place of residency, travelling 
behaviour, moved health jurisdiction during treatment) 
n= 4 
39 40 46 59  
Clinical Disease site/presentation n= 6 
37 38 40 48 56 54 
Smear & sputum culture result n= 6 
38 47 48 57 58 54 
Treatment resistance n= 3 
46 48 60 
TB history n= 9 
37 38 40 43 45 52 53 56 60 
HIV status n= 9 
44 46 48 49 50 51 53 56 55  
Substance use/issues n= 17 
37 39 42 44 45 46 47 48 50 51 52 53 56 57 59 55 60 








Determinant grouping variable Studies assessing determinant grouping 
variable:  
Health systems Route to care n= 3 
51 58 60 
Treatment provider (e.g. treated at referral hospital, 
treated by private health provider) 
n= 2 
45 54  
HCP perceptions of patient knowledge n=3 
47 51 52  
Other (e.g. hospitalisation, health insurance status, 
time from culture confirmation to presentation)  
n= 3 
47 50 54  
Psychosocial factors Mental health problems n= 3 
42 47 57 
Having close relationships n= 1 
60 
Note. HCP= health care professional, SES= socioeconomic status, TB= tuberculosis  
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Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 






























Age Under 30 y/o 37  
[16-24] 






































Over or equal 65 y/o 
   
42§,||  
[30-59] 




















 Other (e.g. unspecified, 
broad range) 











Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 



































Sex Male [Female] 50*  59* 40 44   Male [Female]       44  
51*  58 48*  43*  




Ethnicity Hispanic  45*  
[non-Hispanic 
Black]  




Asian [White] 40*,††† 
 
40*,‡‡‡  
48*   Asian [White] 
   
40*,§§§  















   
Ethnicity category non-
specific (e.g. White, Asian, 
or Hispanic) [NS] 
45  
  
   
Other [White] 40*  
  
42||  Other [White] 
   
42§  
  Black Caribbean [White]       42||  
Nationality/ 
origin‡ 
Europe 37||||||  
[South Asia] 












Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 






































North America and 
Oceania [Abroad] 
   
48*   North America and 
Oceania [South Asia] 
   
37  
 







   
58‡‡‡‡  
[Dutch] 
East Mediterranean [Dutch] 58  
   
 East Mediterranean [South 
Asia] 
   
37  
 
Foreign-born [UK born] 38*  
   
 Foreign-born [Japan born] 
   
54  
Other/country of birth 
unknown [Dutch] 
58  
   
 Other/Country of birth 
unknown [Japan born] 
  
54    
Latin, South, Central 
America or Caribbean 
   
37  
[South Asia] 








Immigrant or migrant [native] 49  
  
   Immigrant or migrant [native] 














   
Migrant 5+ years [UK born] 
   
40*   




   
Asylum seeker [not in category] 
   
58  
Time in resident country 
unknown [UK born] 
40*  
  





Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 































Living alone 51  
[with family] 





abode [has fixed abode] 
37  60||||||||  
 
58  Homelessness/no fixed 
abode [has fixed abode] 
  
55 54 










































Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 
































Shared accommodation [with 
family] 















Active occupational status 
[retired] 
51*           





   Unemployed [Full/part- time 
employed] 






     







Occupation HCP [Full/part- time employed] 
  
54¶¶¶¶  54*****   HCP [Full/part- time employed] 
   
54††††† 
Housemaker [Full/part- time 
employed] 
   
54   
 Job/employment unknown 
[Full/part- time employed] 
  
54     




   
   Student [Full/part- time employed]     
 
54  
SES indices  Receiving social welfare 
benefit [not in category] 
   
54   
 
Low SES level 




   
Townsend score high 
deprivation [Townsend score least 
deprivation] 






Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 





























Primary education only 
[2nd/3rd level education only] 
39* 
  
   
SES Level 4/5 (high 
deprivation) [SES Level 1,2, or 3] 
43* 
  
   




   
   Townsend score between 
low and high deprivation 
[Townsend score least deprivation] 
      38*  
Other Living outside of London 
[living in London] 













    
Moved health jurisdiction 
within state during Tx [not 
moving during Tx] 


















Extra-pulmonary [not in 
category] 
   
48*   
 













Smear +ve and/or culture 
+ve 
   
38*  
[-ve] 
 Smear +ve and/or culture 
+ve 
47***   
[not +ve in 












Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 






























[not +ve in 




















   Smear -ve and/or culture –
ve [+ve] 
   
48*  
Tx resistance MDR  46††,‡‡ 
[NS] 




Other resistance [no resistance] 
   
48*   Other resistance [no resistance] 











 Previous TB [no history]       38*  
 
Previous TB Tx [no previous Tx] 
 
45  
   
   
52   
53   
43* 
Unknown previous TB 






Previous TB Tx default [no 
previous default] 
43* 
   
 
 








HIV infection [HIV negative] 50*  
 
  48*   HIV infection [HIV negative]       49*  
51*  
55 
HIV status known/missing 
[HIV negative] 
   
51*     
 48* 
HIV negative [NS] 56  
   
 
AIDS [HIV negative] 
   






Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 





























AIDS (or AIDS related 
complex) [NS] 
46†† 46‡‡ 
HIV infection via IDU 
transmission [sexual transmission] 
53*  
 




Alcohol use [NS] 37     
 
   
  Alcohol misuse/addiction 44  
[NS] 
39* 

























 Illicit drug use [NS] 









Illicit drug misuse/addiction 51  
[No IDU] 
   


















Drug use unknown 51  
[No IDU] 








Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 





























Any substance misuse 
(including IDU, non-IDU, 
and alcohol) [NS] 
46††,‡‡ 
  
   
Being treated with 
methadone [NS] 
45      
Alcohol problems in 
hospital [Not in category] 
  60*      
Other 
  
Relapse (unspecified) [NS] 57*          
  Diabetes co-morbidity [not in 
category] 










    
Source – specialist [primary 
care] 
   
51*  
 
Source – other [primary care] 
   
51*   






Detection of TB by 
screening [other detection] 
 
    58  
Tx provider Tx started in OP 





   
Private health provider 
[provider was DOH] 
45* 
   
 
Private health provider with 
low volume of patients 
[private health provider with high volume] 
45* 
  
   




   
HCP 
perception of 
Had previous Tx 











Potential risk factor Strength of evidence  Potential protective 
factor 
Strength of evidence 































Had difficulty with previous 
Tx comprehension† [easy 
previous Tx comprehension] 
51 
   
   
Poor understanding [NS] 52 
   
 










Hospitalised (includes IP 
care) [not hospitalised] 
  
  50*   
Months from +ve culture to 




 Months from +ve culture to 
DOH interview [NS] 
   
47*** 
No health insurance [has 
health insurance] 
   





Mental health problems [NS] 42§,||  
   
 Mental health problems [NS] 47***  
  




  Having close relationships 
[no close relationships] 
 60*    
Note. Where variable levels are non-binary, baseline comparator is given italicised in square brackets, either next to variable level 
or individual study reference where this differs between studies. No data was extracted from 36. Some variables could not be 
extracted from 58 (urban residence, previous default from TB Tx, homelessness, alcohol addiction, drug addiction, occupation, 
travel to endemic areas, disease site, HIV co-infection), 57 (age), 43 (age, nationality (other)), 60 (sex, age, disease site, cavitary 
disease, sputum smear result), and 39 (drinking (moderate drinking)). +ve= positive, -ve= negative, DOH= Department of Health, 
HCP= healthcare professional, IDU= intravenous drug use, IP= inpatient, MDR= multidrug-resistant, NS=not specified, OP= 
outpatient, SES= socioeconomic status, TB= tuberculosis, Tx= Treatment *=univariate/ bivariate analysis. †=Determinants were not 
further defined. ‡=nationality: studies 37, 48, and 38 comparator is not the study country, for studies 58, 59, 43 and 54, comparator is 
study country. §=outcome: outcome: non-adherent in first 2 months, ||= outcome: loss to follow-up within 6 months, ¶= age: 35-44, 
**= age: 55-64, ††= outcome: excludes patients who moved during study, ‡‡= outcome: includes patients who moved during study, 
§§= age: 75, ||||= age: 45-54, ¶¶= outcome: default with return to therapy, ***= outcome: default without return to therapy, †††= 
ethnicity: Indian, ‡‡‡= ethnicity: Pakistani, §§§= ethnicity: Bangladeshi, ||||||= nationality/origin: born in Central Europe, ¶¶¶= 
nationality/origin: born in West Europe, ****= nationality/origin: born in East Europe, ††††= nationality/origin: Somalian and other 
45 
 
African, ‡‡‡‡= nationality/origin: Moroccan, §§§§= place of residence: staying in transient hostel after discharge, ||||||||= place of 
residence: homeless prior to admission, ¶¶¶¶= HCP: Nurse, *****= HCP: Physician, †††††= HCP: Other HCP, ‡‡‡‡‡= Smear: 
culture/smear not done, §§§§§= Smear: culture/smear unknown.  
